ReviewPharmaceutics2023
Recent Advances in Intranasal Liposomes for Drug, Gene, and Vaccine Delivery.
Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.
- Flavonoids in Nasal Therapeutics: Biological Activities, Delivery Challenges, and Formulation Strategies-A Systematic Review.Phytotherapy research : PTR · 2026Pooled it
- Intranasal drug delivery to the brain for neurodegenerative diseases: Current efforts and challenges in delivery platforms and modeling.Advanced drug delivery reviews · 2026Review
- Nose-to-Brain Nanocarriers for Migraine Management: A Comprehensive Review of Drug Delivery Strategies and Translational Challenges.Current medical science · 2026Review
- Systematic Design and Evaluation of Nasal Drug Delivery for Central Nervous System Disease from Experimental to Clinical Application.Pharmaceutics · 2026Review
- Polyphenol-Based Nanomedicine: Versatile Platforms for Immune Modulation and Therapeutic Delivery.Molecules (Basel, Switzerland) · 2026Review
- Cannabidiol in Gliomas: Therapeutic Potential and Nanocarrier Strategies, with an Emphasis on Vesicular Delivery Systems.Molecular pharmaceutics · 2026Review
- Transforming therapeutics through biomaterials: A comprehensive insight into biomaterials' role in effective drug delivery and healthcare advancement.Biomaterials translational · 2026Review
- Non-viral gene delivery systems for osteoarthritis therapy.Biomaterials translational · 2026Review
- Nanoparticle-Based Targeted Drug Delivery Systems for Allergic Rhinitis: A Comprehensive Review.International journal of nanomedicine · 2026Review
- Calcium Nanoliposome Improves Glycemic Control in a Mouse Diabetes Mellitus Model.Pharmaceutical nanotechnology · 2026Article
- Soluplus Stabilized Amorphous Dispersions for Enhanced Oral Absorption of Felodipine.Current drug delivery · 2026Article
- Lipid-Based Nanocarriers for Intranasal Delivery: Revolutionizing Neurological Disorder Therapies.Current topics in medicinal chemistry · 2026Review
- Beyond dysbiosis: microbial metabolites as key remodelers of nasal mucosal immune tolerance in chronic rhinosinusitis.Frontiers in immunology · 2026Review
- Chemical strategies for brain delivery of genomic therapy.Nature reviews. Chemistry · 2025Review
- Development of Propofol-Encapsulated Liposomes and the Effect of Intranasal Administration on Bioavailability in Rabbits.Pharmaceutics · 2025Article
- Article
- In Vitro Comparative Study on Oppositely Charged Donepezil-Loaded Intranasal Liposomes.Pharmaceutics · 2025Article
- Recent Advances in Nose-to-Brain Gene Delivery for Central Nervous System Disorders.Pharmaceutics · 2025Review
- Liposome-Enabled Nanomaterials for Muscle Regeneration.Small methods · 2025Review
- Recent Advances in Donepezil Delivery Systems via the Nose-to-Brain Pathway.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Liposomes are safe, biocompatible, and biodegradable spherical nanosized vesicles produced from cholesterol and phospholipids. Recently, liposomes have been widely administered intranasally for systemic and brain delivery. From the nasal cavity, liposome-encapsulated drugs and genes enter the systemic circulation primarily via absorption in the respiratory region, whereas they can be directly transported to the brain via the olfactory pathway. Liposomes can protect drugs and genes from enzymatic degradation, increase drug absorption across the nasal epithelium, and prolong the residence time in the nasal cavity. Intranasal liposomes are also a potential approach for vaccine delivery. Liposomes can be used as a platform to load antigens and as vaccine adjuvants to induce a robust immune response. With the recent interest in intranasal liposome formulations, this review discusses various aspects of liposomes that make them suitable for intranasal administration. We have summarized the latest advancements and applications of liposomes and evaluated their performance in the systemic and brain delivery of drugs and genes administered intranasally. We have also reviewed recent advances in intranasal liposome vaccine development and proposed perspectives on the future of intranasal liposomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.